{
  "outcomes_metadata": {
    "timestamp": "2025-10-02T16:13:27.783049",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "consolidation_type": "outcomes",
    "data_split": "test",
    "total_unique_outcomes": 49,
    "source_countries": [
      "DE",
      "DK",
      "EN",
      "EU",
      "FR",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_outcomes": {
    "efficacy": {
      "survival_endpoints": [
        "overall survival (OS)",
        "prolonged survival",
        "event-free survival",
        "eventless survival",
        "progression-free survival (PFS; RECIST v1.1)",
        "progression-free survival (blinded independent central review)",
        "progression-free survival (independent, blinded review panel; RECIST 1.1)",
        "progression-free survival (PFS)",
        "centrally-assessed progression-free survival",
        "investigator-assessed progression-free survival",
        "progression-free survival",
        "time to death"
      ],
      "response_measures": [
        "objective response rate (ORR; RECIST 1.1)",
        "objective response rate (independent review panel)",
        "objective response rate (ORR)",
        "overall response rate (ORR)",
        "response rate",
        "disease control rate (proportion of patients with complete, partial, or stable disease response â‰¥ 5 weeks)",
        "rate of disease control",
        "delay to response time (delay from initiation of treatment to first complete or partial response)",
        "duration of response (DoR; RECIST 1.1 or death from any cause)",
        "duration of response (DoR)",
        "duration of treatment"
      ],
      "progression_measures": [
        "time to progression (TTP)",
        "time to progression",
        "time to next treatment (TTNT)",
        "time to next treatment",
        "progression after next line of therapy (PFS2)"
      ]
    },
    "safety": {
      "adverse_events": [
        "adverse events (CTCAE v5.0)",
        "adverse events (Common Terminology Criteria for Adverse Events, CTCAE v5.0)",
        "adverse events",
        "adverse effects",
        "adverse effects impacting health-related quality of life",
        "side effects",
        "adverse drug reactions",
        "adverse event rate",
        "adverse event rate grade 3-4",
        "dropout rate",
        "mortality-related toxicity",
        "intolerance",
        "need for alternative therapy",
        "diarrhoea",
        "ALT increase",
        "AST increase",
        "neutropenia",
        "fatigue",
        "febrile neutropenia",
        "vision loss",
        "serious side effects on the skin",
        "pain",
        "ulceration"
      ],
      "serious_events": [
        "serious side effects on the skin",
        "febrile neutropenia",
        "mortality-related toxicity",
        "vision loss"
      ],
      "discontinuations": [
        "dropout rate",
        "intolerance",
        "need for alternative therapy"
      ]
    },
    "quality_of_life": {
      "patient_reported_outcomes": [
        "EORTC QLQ-C30",
        "EORTC QLQ-LC13",
        "BPI-SF",
        "FACT-G GP5",
        "PGI-C",
        "Patient Global Impression of Change (PGIC)",
        "Patient Global Impression of Severity (PGIS)",
        "NSCLC Symptom Assessment Questionnaire (NSCLC SAQ)",
        "EQ-5D-5L"
      ],
      "functional_status": [
        "Karnofsky performance status",
        "ECOG performance status"
      ],
      "symptom_measures": [
        "symptomatology",
        "symptom control",
        "pain",
        "anxiety",
        "health status",
        "preservation of quality of life",
        "health-related quality of life",
        "health-related quality of life (measured by time to death)",
        "time to deterioration of overall health status"
      ]
    },
    "economic": {
      "cost_effectiveness": [
        "cost per QALY achieved"
      ],
      "utilities": [
        "quality-adjusted life years (QALYs)",
        "health-state utilities",
        "time-to-death utilities",
        "disutility for intravenous treatment"
      ],
      "resource_utilization": [
        "duration of treatment"
      ]
    },
    "other": {
      "exploratory_endpoints": [],
      "biomarkers": []
    }
  }
}